{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042390","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.237678+00:00","generated_at":"2026-06-11T12:10:48.266623+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx FDA partial clinical hold lifted for iMMagine-1; Q2 net loss $23.9M","bullets":["FDA lifted partial clinical hold on CART-ddBCMA Phase 2 iMMagine-1 trial after patient death and protocol modifications.","Cash, cash equivalents, and marketable securities $506.5M; funds operations through BLA filing into 2026.","Collaboration revenue of $14.3M from Kite partnership; R&D expenses $28.3M, G&A $15.5M.","Net loss improved to $23.9M vs $30.8M in Q2 2022; preliminary iMMagine-1 data expected 2H 2024.","Expanded bridging therapies allowed under revised protocol; all 17 previously enrolled patients dosed during hold."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042390","json":"https://secwatch.observer/filing/0000950170-23-042390.json","markdown":"https://secwatch.observer/filing/0000950170-23-042390.md","text":"https://secwatch.observer/filing/0000950170-23-042390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/0000950170-23-042390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/aclx-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:10:48.266623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e65dff5816006c29984c881b0411fad77586f01d","claim":"Arcellx, Inc. reported second quarter ended June 30, 2023 results: revenue $14.3 million, net income $23.9 million.","evidence_excerpt":"Collaboration revenue was $14.3 million and $0 for the quarters ended June 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/0000950170-23-042390-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$14.3 million"},{"label":"Net income","value":"$23.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}